TR200500749T2 - Dna mutajenik hasarının tamiri - Google Patents

Dna mutajenik hasarının tamiri

Info

Publication number
TR200500749T2
TR200500749T2 TR2005/00749T TR200500749T TR200500749T2 TR 200500749 T2 TR200500749 T2 TR 200500749T2 TR 2005/00749 T TR2005/00749 T TR 2005/00749T TR 200500749 T TR200500749 T TR 200500749T TR 200500749 T2 TR200500749 T2 TR 200500749T2
Authority
TR
Turkey
Prior art keywords
repair
mutagenic damage
dna mutagenic
methods
damage
Prior art date
Application number
TR2005/00749T
Other languages
English (en)
Turkish (tr)
Inventor
Edmund Kelly Graham
Husband Alan
Walker Cath
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of TR200500749T2 publication Critical patent/TR200500749T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
TR2005/00749T 2002-09-06 2003-09-05 Dna mutajenik hasarının tamiri TR200500749T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002951271A AU2002951271A0 (en) 2002-09-06 2002-09-06 Repair of dna mutagenic damage

Publications (1)

Publication Number Publication Date
TR200500749T2 true TR200500749T2 (tr) 2005-10-21

Family

ID=27671591

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2005/00749T TR200500749T2 (tr) 2002-09-06 2003-09-05 Dna mutajenik hasarının tamiri

Country Status (11)

Country Link
US (1) US20060153781A1 (https=)
EP (1) EP1534232A4 (https=)
JP (1) JP2006501252A (https=)
CN (1) CN1688285A (https=)
AU (1) AU2002951271A0 (https=)
CA (1) CA2497823A1 (https=)
CZ (1) CZ2005136A3 (https=)
MX (1) MXPA05002519A (https=)
NO (1) NO20051605D0 (https=)
TR (1) TR200500749T2 (https=)
WO (1) WO2004022023A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104643057A (zh) 2002-07-24 2015-05-27 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
EP1542654A4 (en) * 2002-09-23 2008-12-17 Novogen Res Pty Ltd TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
CA2738510A1 (en) * 2008-07-30 2010-02-04 Novogen Research Pty Ltd 6-substituted isoflavonoid compounds and uses thereof
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
CN114831981A (zh) * 2021-02-02 2022-08-02 上海交通大学 一种ERβ选择性激动剂在抗肿瘤中的应用
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AUPP868599A0 (en) * 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
DE10121375B4 (de) * 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) * 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen

Also Published As

Publication number Publication date
NO20051605L (no) 2005-03-30
NO20051605D0 (no) 2005-03-30
EP1534232A4 (en) 2008-12-24
CZ2005136A3 (cs) 2006-04-12
AU2002951271A0 (en) 2002-09-19
EP1534232A1 (en) 2005-06-01
CN1688285A (zh) 2005-10-26
JP2006501252A (ja) 2006-01-12
CA2497823A1 (en) 2004-03-18
WO2004022023A1 (en) 2004-03-18
US20060153781A1 (en) 2006-07-13
MXPA05002519A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
IL164249A0 (en) Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
TW200507484A (en) An ultra-wideband transceiver architecture and associated methods
BR0300840B1 (pt) conjunto de conduto protetor.
MXPA05013822A (es) Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
TR200500749T2 (tr) Dna mutajenik hasarının tamiri
ATE553185T1 (de) Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
WO2001096606A3 (en) Identification of genes and compounds for treatment of cancer
CA101715S (en) Multiple-bladed thicket knife
MXPA03008076A (es) Isoflavonas dimericas.
HUE052154T2 (hu) Rövid felezési idejû C1 inhibitor tranziens kezeléshez
DK1599205T3 (da) PTEN-inhibitor eller Maxi-K-kanalåbner
DE50303356D1 (de) Gasgenerator
WO2004031402A3 (en) Methylation profile of cancer
NO20020357D0 (no) Antenneanordning
DE50304273D1 (de) Gasgenerator
WO2003065997A3 (en) Anti-infarction molecules
ES1052858Y (es) Tensor terminal de elementos filiformes en general.
EA200600609A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
FI20031392L (fi) Hakkuri- tai murskainlaitteisto, erityisesti lastuhakkuri
DE60335525D1 (de) 2,3-Diaryl-Pyrazolidine Derivate als Neurotensin abbauende Enzyme-Inhibitoren
DE60319388D1 (de) C6- UND C9-SUBSTITUIERTE CHROMENOÄ4,3-cÜISOXAZOLIN
NO20044186L (no) Peptid-deformylaseinhibitorer
NO20053188D0 (no) Fremgangsmate og anordning for multibruker interferenskansellering.
ATE264308T1 (de) Aminoalkyl-3,4-dihydrochinolin-derivate als no synthase inhibitoren
NO20054289D0 (no) Imiciazo[4,5-b]kinolinderivater og dem anvendelse som NO-syntaseinhibitorer